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Abstract
Introduction: The goal of this study was to understand indi-
viduals with cerebral palsy (CP) and their family’s attitudes 
and preferences to genomic research, including internation-
al data sharing and biobanking. Methods: Individuals with 
CP and their family members were invited to participate in 
the web-based survey via email (NSW/ACT CP Register) or via 
posts on social media by Cerebral Palsy Alliance, CP Research 
Network, and CP Now. Survey responses included yes/no/
unsure, multiple choices, and Likert scales. Fisher’s exact and 
χ2 tests were used to assess if there were significant differ-
ences between subgroups. Results: Individuals with CP and 
their families (n = 145) were willing to participate in genom-
ics research (68%), data sharing (82%), and biobanking ef-
forts (75%). This willingness to participate was associated 
with completion of tertiary education, previous genetic test-
ing experience, overall higher genomic awareness, and trust 
in international researchers. The survey respondents also ex-
pressed ongoing communication and diverse information 
needs regarding the use of their samples and data. Major 
concerns were associated with privacy and data security. 
Discussion: The success of genomic research and interna-
tional data sharing efforts in CP are contingent upon broad 
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support and recruitment. Ongoing consultation and en-
gagement of individuals with CP and their families will fa-
cilitate trust and promote increased awareness of genomics 
in CP that may in turn maximize participant uptake and re-
cruitment. © 2021 The Author(s)
Published by S. Karger AG, Basel
Introduction
Genomic technology has transformed and accelerated 
our understanding of human health and disease. How-
ever, genomic research requires vast quantities of data to 
achieve adequate sample size for analyses. To facilitate 
rapid discovery and translation of genomics to end care 
for individuals, researchers are strongly encouraged to 
share their participant research data more broadly. As a 
result, advances in genomic research depend to some ex-
tent upon large-scale international collaboration com-
bined with biobanking and data sharing. However, ensur-
ing that research participants and their families are ade-
quately informed about the collection, use, and storage of 
their biological material and data is challenging [1].
Cerebral palsy (CP) is a neurological condition that af-
fects movement and posture. Historically, CP was thought 
to be caused by brain injury around the time of birth. 
However, studies of total populations of children with CP 
(which have occurred in the intervening years) have now 
firmly established that CP comprises many types of brain 
injuries/maldevelopments with etiological pathways 
known, uncertain, and for some still unknown [2]. Ge-
nomic research in CP over the last decade has demon-
strated a clear and important role of genetic factors in CP 
etiology [reviewed in [3]). The importance of genetics for 
CP is not only in understanding precise and timely etiol-
ogy, but opening future opportunities for prevention, 
prognosis, and personalized treatment. To aid precision 
medicine in CP, biobanking and data sharing platforms 
will form an integral part of the international CP genom-
ics research landscape [4]. The success of these efforts will 
rely heavily on families’ willingness to participate in ge-
nomics research and consumer/family engagement to ad-
dress the complexities associated with international bio-
banking and data sharing. However, public consultation 
with individuals with CP and their families to elucidate 
attitudes, concerns, perceptions, and information needs 
has not yet been undertaken.
Prior studies have examined the perspectives of people 
with cancer, rare disease, or the general public to genom-
ic studies; however, relatively little is known about the at-
titudes of individuals with CP and their family members 
toward participation. Therefore, this survey sought to 
characterize the views of people with CP and their fami-
lies to determine their: (1) willingness to participate in 
genomics research and what information they need to 
make this decision; (2) views on international data shar-
ing and biobanking of their biological samples; (3) how 
they prefer to receive genomic results and research up-
dates. The results of this study will guide the development 
and quality of data sharing platforms and biobanks in CP.
Methods
The study was conducted in partnership with 3 Research Part-
ners from CP Quest, an initiative where people with CP and fam-
ily members collaborate with researchers to improve the quality of 
research, and ensure research is meaningful for families. The 3 
Research Partners are all co-authors of this study and included a 
young adult with CP (S.O.), an adult with CP (S.M.), and a parent 
of an adult with CP (M.T.).
The reporting of this survey follows the Checklist for Reporting 
Results of Internet E-Surveys (CHERRIES) (see online suppl. Ta-
ble 1; all online supplementary material is available at www. 
karger.com/doi/10.1159/000518942), which aims to improve the 
quality of web-based survey reporting [5].
Survey Development
We reviewed the literature and conducted semi-structured in-
terviews with our Research Partners to identify major themes to be 
examined in genetic studies, biobanking, and data sharing. The 
draft survey questions were developed, and the survey piloted, re-
viewed, and refined in conjunction with the Research Partners. 
The pilot ensured that complexity was minimized, duplications 
deleted, and questions reduced so that the survey was as stream-
lined as possible. There were a total of 71 questions, with a maxi-
mum of 8 questions per page across 15 pages. The final survey 
consisted of multiple-choice, Likert scale, open-ended text box 
questions and included adaptive questioning logic. Our items did 
not include a “non-response” option such as, “I’d rather not say”; 
however, none were compulsory. We included background infor-
mation on genetics, biobanking, and data sharing for survey re-
spondents to review. The survey was available in English only.
The introduction information for participants included the 
purpose of the survey, who the investigators were, how the infor-
mation would be stored, and the length of time it would take to 
complete the survey.
The survey was open for a 3-month period, was voluntary, and 
no incentives were offered. The participants were individuals with 
CP and parents or carers of individuals with CP. Invitations to take 
part in the electronic survey were sent via email to the NSW/ACT 
CP Register (n = 2,300), CP Quest (n = 50), and posted on social 
media platforms for CP Alliance (Australia), CP Research Net-
work (USA), CP Now Foundation (USA), and Reaching for the 
Stars (USA). This was a convenience sample and we are unable to 
identify the total number of people that the advertising of the study 
reached. See online suppl. Material for survey announcements. 
Participants were able to review and change their responses over 




this time period. Responses were automatically captured by RED-
Cap. We considered the content of this survey to be low risk for 
multiple entries from the same person; therefore, we did not use 
cookies or complete IP address checks for this purpose. The project 
has ethics approval from the University of Sydney Human Re-
search and Ethics Committee, a National Health and Medical Re-
search Council accredited HREC (2020/470).
Analysis
Records were removed for analysis if demographic data were 
incomplete or no survey data were captured (i.e., people logged in 
to look at the survey but did not participate). Incomplete records, 
such as those in which a participant did not answer every question, 
were included in analysis. If 60% of respondents replied to a ques-
tion, it was considered “answered” and was analyzed.
Demographics and survey responses were summarized using 
descriptive statistics. For some statistical analyses, we dichoto-
mized the categorical variables into yes (“yes”) versus no 
(“no”/“unsure”). Trust of the international research community, 
originally a 5-point Likert scale, was dichotomized to “do not 
trust” (1–2) and “do trust” (4–5). To investigate factors associated 
with willingness to participate, we split the respondents in those 
willing to participate or those unsure or unwilling to participate 
based on their answer to, “Would you be willing to donate a bio-
logical sample for a CP genomics study”? The genomic awareness 
score was developed based on the aggregated responses to 4 ques-
tions. Each question could only be answered yes, no or unsure. The 
questions: (1) are you familiar with the word DNA; (2) are you fa-
miliar with the word gene; (3) are you familiar with the word ge-
nome, and; (4) are you aware that your genetic testing results may 
have implications for your extended family. A score of zero was 
recorded for each question the respondent said no or unsure, and 
a score of 1 was recorded for each yes. The lowest possible aggre-
gated score was zero and the maximum aggregated score was 4. A 
score of 0–1 was designated “no awareness,” a score of 2 was as-
signed “limited awareness,” a score of 3 was “somewhat aware,” 
and a score of 4 was assigned “very aware.”
Fisher exact test and χ2 tests were used to test for potential con-
founders between demographics. To test if there was a difference 
in the age of those willing to participate or not, we used an indepen-
dent samples t test. To test the difference between dichotomous 
variables and willingness to participate, we used Fisher’s exact test. 
Likert scale responses were summarized using the package “likert” 
[6] in R (Rx64, version 3.5.0, http://www.R-project.org/). To test 
for differences in all other multinomial variables and willingness to 
participate, we used the χ2 test of homogeneity. All statistical tests 
were 2-sided, where p < 0.05 were considered statistically signifi-
cant. Error bars are 95% confidence intervals for all graphs. Analy-
ses were performed using IBM SPSS Statistics 24 (IBM).
Results
Participant Characteristics
Of the 183 people that opened the survey, 145 indi-
viduals completed the demographic information and re-
sponded to the survey. Completion rate for each question 
ranged between 65 and 100%. The characteristics of the 
participants are shown in Table 1. Our cohort was gener-
ally well-educated, predominantly female, and parents of 
an individual with CP. There were no significant differ-
ences between demographic measures, and they are dis-
tributed independently of each other (data not shown). A 
Table 1. Survey participant demographics and willingness to take part in a CP genomics study
Participant characteristics Total
n (%)
Willingness to participate in a hypothetical CP genomic study
yes no/unsure statistics
Total, N (%) 145 (100) 94 (68) 49 (32)
Agea
Mean (SD) 41 (10 yr 6 mo) 41 (9 yr 9 mo) 44 (12 yr 2 mo) 2.7±2.1 [SEM], t(67.57) = 1.286, p = 0.203
Genderb, N (%)
Female 127 (88) 83 (88) 8 (84)
Male 18 (12) 11 (12) 7 (16) 0.527
Country of residenceb, N (%)
Australia 92 (63) 58 (62) 29 (64)
USA 45 (32) 31 (33) 14 (31)
Other 8 (5) 5 (5) 2 (4) 0.944
Educationc, N (%)
Did not attend university 38 (26) 19 (20) 17 (37)
Completed university 107 (74) 75 (80) 28 (63) χ2(1) = 4.892, p = 0.038
Relationship to CPb, N (%)
An individual with CP 26 (18) 16 (17) 10 (22)
A parent of an individual with CP 110 (76) 72 (77) 32 (71)
Other (e.g., sibling, carer) 9 (6) 6 (6) 3 (7) 0.753
CP, cerebral palsy; SD, standard deviation. a Independent t test. b χ2 analysis. c Fisher’s exact analysis.
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quarter of survey participants (n = 40) had previous ge-
netic testing experience and overall 53% (n = 77) of the 
participants were “somewhat aware” or “very aware” 
about genomics (Table 2).
Willingness to Participate in Genomic Studies Was 
Associated with Higher Education Attainment, 
Previous Genetic Testing, Genomics Awareness, and 
Trust in International Researchers
When the participants were asked if they would be 
willing to participate in a genetic study of CP, two-thirds 
of the respondents’ indicated that they were willing (Ta-
ble 1). Of those willing to participate, >65% stated their 
reasons as “wanting to contribute to the scientific knowl-
edge of CP.” Willingness to participate in a CP genetic 
study was not associated with age, gender, country of res-
idence, or the respondent’s relationship to CP. However, 
willingness to participate was associated with tertiary ed-
ucation completion (χ2(1) = 4.892, p = 0.038), previous 
genetic testing (χ2 = 4.464, p = 0.037), and overall genom-
ic awareness (χ2 = 11.060, p = 0.004).
When examining whether trust in the researcher 
played a role in respondent’s willingness to participate, 
we found was no difference between willingness to par-
ticipate and trust in researchers from the respondents’ 
home country (p = 0.469). However, we did observe a sig-
nificant difference between willingness to participate and 
trust in the international research community (χ2(2) = 
13.343, p = 0.001).
Information about the Purpose of the Study and 
Protecting Participant’s Privacy Are the Most Important 
Pieces of Information for Participants to Receive
Figure 1 shows what information respondents consid-
ered important in order to consent to participate in a CP 
genetics study. More than 80% of respondents noted that 
the most important (moderately important/very impor-
tant) information they needed, when being asked to join 
Table 2. Traits of survey respondents associated with willingness to participate in a CP genomics study
Participant characteristics Total
n (%)







Yes 40 (28) 33 (39) 7 (19)
No/unsure 80 (55) 51 (61) 29 (81) χ2(1) = 4.464, p = 0.037
Did not respond 25 (17)
Genomic awarenessb
Very aware* 15 (10) 14 (16) 1 (3)
Somewhat aware 62 (43) 45 (52) 17 (45) χ2(2) = 11.06, p = 0.004
Limited awareness* 47 (32) 27 (31) 20 (53)
Did not respond 21 (14)
Trust in researchers homeb
Yes 84 (58) 66 (85) 18 (75)
Neutral 16 (11) 11 (14) 5 (20)
No 2 (1) 1 (1) 1 (5) 0.469
Did not respond 43 (30)
Trust in researchers awayb
Yes* 61 (42) 52 (67) 9 (39)
Neutral 27 (19) 21 (27) 6 (26) χ2(2) = 13.343, p = 0.001
No* 13 (9) 5 (7) 8 (35)
Did not respond 44 (30)
Receiving personalized genetic results influence your decision to participateb
Yes* 35 (31) 21 (25) 14 (47) χ2(2) = 26.394, p < 0.001
No* 55 (49) 52 (62) 3 (10)
Unsure 23 (20) 10 (12) 13 (43)
Did not respond 32 (22)
CP, cerebral palsy. * Are the 2 groups that post hoc analysis showed the differences between groups. a Fisher’s 
exact analysis. b χ2 analysis.




a genetic study were: the purpose of the study (Q1), how 
their confidentiality was protected (Q2–3), what would 
happen in the event of a data breach (Q4), who was ac-
cessing their de-identified information (Q5), and the 
risks and benefits of participating (Q6).
When we considered these results based on willing-
ness to participate, we observed differences in what in-
formation respondents’ thought was important. Of those 
willing to participate, only Q1–4 had >80% ranking these 
items as “moderately important/very important.” Where-
as those unsure or unwilling to participate indicated that 
Q1–9 and Q11 (Fig. 1) were “moderately important/very 
important.” Information about the study purpose (Q1) 
was important for both groups, although those unsure or 
unwilling to participate were also interested in the risk 
and benefits of participating in genetic research (Q6) and 
whether they would receive their genetic results (Q11). 
Data security and privacy were predominant informa-
tion needed by both groups (Q2–Q4), and those unsure 
or unwilling also indicated that information about what 
projects their data would be accessed for (Q5), how their 
data are securely stored (Q7), how researchers gain ac-
cess to the database (Q8), and how they could withdraw 
from the database if they changed their mind (Q9) was 
also very important in their decision-making to partici-
pate.
Research Participants Want Regular Communication
Figure 2a shows that nearly 50% of survey respondents 
were interested in receiving updates about the research 
project they were recruited to every 3 months or sooner. 
These findings were irrespective of any participant demo-
graphics or other characteristics. The great majority of 
survey respondents (95%, n = 107) were interested in re-
ceiving their personalized genetic results, most of whom 
wanted to receive all their genetic findings, including in-
cidental findings (n = 98) (Fig.  2b). We also examined 
whether offering genetic results may influence a respon-
dent to participate in a CP genomics study. Figure 2c 
shows that nearly 50% of respondents would not be influ-
enced by the prospect of receiving their personalized ge-
netic results. However, when these data were stratified by 
willingness to participate in a CP genomics study, we did 
observe that those who were unsure or unwilling to par-
ticipate in a CP genomics study were more likely to be 
influenced by the offer of receiving their personalized re-
Fig. 1. Respondents rank the importance of information given in 
information sheets about genetic studies, biobanking, and data 
sharing. Q1: Purpose of the genetic study (n = 107), Q2: Data ano-
nymization steps of database (n = 102), Q3: Confidentiality of their 
information in the genetic study (n = 109), Q4: Data breach man-
agement plan of database (n = 102), Q5: What research projects 
their de-identified data have been accessed for (n = 102), Q6: Risk 
and benefits of participating in genetic research (n = 108), Q7: How 
data are securely stored, Q8: How researchers gain access to data 
in database (n = 102), Q9: Withdraw de-identified data from data-
base (n = 102), Q10: Commercial profits (n = 125), Q11: Return 
genetic results (n = 124), Q12: Where sample processed/sequenced 
(n = 107), Q13: Acknowledged for participating (n = 108). Percent-
ages from left to right represent “not important/less important,” 
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sults χ2(2) = 26.394, p < 0.001 (Table 2). There was no 
further association between education, genome aware-
ness, or prior genetic testing experience (data not shown).
Respondents Are Supportive of Data and Sample 
Sharing, but Want to Be Kept Up-To-Date about How 
Their Data or Samples Are Being Used
More than 80% of survey respondents were willing to 
share their de-identified data (Fig.  3a). Furthermore, 
when we asked respondents to specify who they would 
be willing to share their de-identified data with, >60% 
were supportive of international data sharing (Fig. 3b). 
We did not find any factors associated with willingness 
to share data internationally, except trust in interna-
tional researchers (χ2(2) = 33.074, p < 0.001). Interest-
ingly, 60% of respondents wanted to be informed each 
time a researcher wished to access their data (Fig. 3c), 
despite also agreeing that a third party or Ethics Com-
mittee could decide on their behalf about who could ac-
cess their de-identified data (Fig. 3d). We observed the 
same trends regarding participants expectations to bio-
banking (Fig.  3e–h), although there was more uncer-
tainty in whether or not they would allow a third party 
to decide on their behalf about who may access their 
samples.
Discussion
CP is a neurodevelopmental condition with complex 
etiologies and causal pathways. Improving our under-
standing of the underlying biology of CP using genomic 
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Fig. 2. Communicating with participants throughout the research project lifecycle. a Shows the communication 
frequency participants prefer to hear from researchers during a project (n = 115). b Shows what types of results 
participants are interested in receiving (n = 107). c Shows the percentage of respondents who would or would 
not be influenced in participating in a genetic study based on the option of receiving their genetic results (n = 
113). CP, cerebral palsy.
Fig. 3. Respondents attitudes toward data sharing and biobanking. 
a (n = 104) and e (n = 139) shows the percentages of participants 
willing or not to share their de-identified data (a) or sample (e). b 
(n = 102) and f (n = 122) show who the participants feel should have 
access to their data (b) and sample (f). c (n = 99) and g (n = 119) 
show the proportions of participants that would or would not like 
to be informed about researchers accessing their data (c) or samples 
(g). d (n = 100) and h (n = 120) show the percentages of partici-
pants that would or would not allow an Ethics Committee to decide 
who may access their data (d) or samples (h). CP, cerebral palsy.
(For figure see next page.)
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technology is contingent upon successful global collabo-
ration and participant trust. This study examines the at-
titudes and perspectives of people with CP and their fam-
ilies regarding their willingness to participate in genomic 
research; what information is important in making these 
decisions; and how frequently participants want to be up-
dated about these efforts. These results are timely given 
the recent establishment of the International Cerebral 
Palsy Genomics Consortium [7] and the rise in clinical 
genomics applications in neurodevelopmental disorders 
around the globe.
In this study, we found that more than two-thirds of 
respondents were willing to participate in a genomic 
study of CP. We observed several differences between 
those willing to participate compared to those unsure or 
unwilling to participate. Those unsure or unwilling to 
participate were associated with lower education attain-
ment, no previous genetic testing experience, a lack of 
general awareness of genomics, and some distrust of in-
ternational researchers. These findings are consistent 
with previous studies that show education [8, 9], prior 
genetic testing [10, 11], increased health literacy [9, 11], 
and trust [9, 11, 12] are important factors in genomic re-
search participation.
Our findings demonstrate that data security and pri-
vacy, which are tightly associated with trust [13, 14], are 
among the most important information needed for our 
cohort. Sanderson et al. [15] noted that in a general 
population cohort that the significant association be-
tween trust, privacy, and willingness to participate were 
abolished when participant information needs were ad-
dressed. Similarly, in a rare disease cohort, participants 
were highly critical of information sheets that were 
vague and lacking in detail [16]. Yet, in a study which 
offered participants increasing levels of information in 
the participant information sheet, only 6% accessed the 
most detailed information despite >20% of participants 
stating they would have appreciated more detail [17]. 
Thus, simply providing additional information on an 
information sheet is unlikely to resolve the fundamen-
tal challenges when dealing with genomic literacy. Fur-
thermore, lengthy information sheets can hinder par-
ticipation, are less likely to be comprehensively read, 
and result in poor understanding and recall by partici-
pants [17, 18].
We must also acknowledge that participants do not 
have equal information needs and that these needs may 
evolve with participation and time. Many of the subse-
quent information needs identified as important by our 
respondents, and the differences we saw between those 
willing to participate and those unsure or unwilling to 
participate, were associated with secondary data-use 
activities (i.e., who had access/what project their data 
contributed to). Importantly, even though many re-
spondents were supportive of international data shar-
ing, this willingness was contingent upon transparency 
and communication. Most participants in our study 
wanted to be informed each time a researcher requested 
access to their de-identified data, even if the decision to 
share was approved by a third party. These findings 
echo those from rare disease cohorts, where partici-
pants want to be informed about what their data or 
samples are contributing to [19–21]. While we did not 
investigate the reason behind this, perspectives from 
people with rare diseases indicate that they are inter-
ested in learning more about their conditions [22], want 
to ensure their data are not being misused [16, 23], and 
that recontact is crucial to building positive relation-
ships between the researchers and participants [16]. Re-
searchers need to consider innovative communication 
approaches, such as dynamic consent [24] and the use 
of multimedia [25] that can service the diversity of in-
formation needs throughout the research partnership. 
Similarly, it will be critical to develop approaches that 
meet the needs of genetically, culturally, and linguisti-
cally diverse populations.
Offering simple, lay language generalized results (pref-
erably written with people with the condition), demon-
strates respect toward the participant, informs partici-
pants about what was learned from the study, and enables 
participant feedback on findings [26]. Furthermore, com-
municating research outcomes with participants can 
build trust in genomic research, which is critical for broad 
recruitment and long-term sustainability of genomics ac-
tivities, such as biobanks and data sharing platforms. 
Others have also reported that participants had greater 
trust in a research team due to sharing research outcomes 
[27] and frequent contact with participants [20]. Re-
searchers and their funding agencies should be vigilant in 
upholding these standards not only because it is respect-
ful best practice but considering distrust in the research 
community (following poor experiences) has been re-
ported as a barrier to repeat participation [9] and may 
discourage continued participation in biobanks or data 
sharing initiatives.
Significance
To our knowledge, this is the first study examining the 
perspectives of people with CP toward genomics research. 
While these findings reiterate many of those from public 




and patient cohorts, denoting that people are by and large 
supportive of genomics efforts, we believe it is essential 
that people with CP and their family’s views are repre-
sented in these discussions. While public opinion on ge-
nomics is important, there is no one size fits all model, 
especially in consideration for people who have lifelong 
conditions, like CP. People with CP, like those with rare 
diseases, have a greater vested interest in their data. These 
individuals, who by and large are experts through their 
own volition, when armed with information make better 
health decisions and improve their health behaviors [28]. 
It can also help foster collaborative relationships between 
the individual and health professionals [29]. As genomics 
becomes more frequently utilized in this diagnostic 
group, we encourage all researchers, clinicians, and scien-
tists to incorporate these findings, as well as people with 
CP and their families, into their research methodology 
and practice.
Limitations
Our study was limited in that we captured the atti-
tudes of potential research participants at a single time 
point and these opinions may change and evolve with 
time. Although these findings are informative, it is well 
known that responses to hypothetical scenarios do not 
always translate to real-life practices [30, 31]. Addition-
ally, some degree of selection bias was unavoidable as we 
did not recruit via random sampling; therefore, potential 
participants who are not supportive of genetic research 
or could not access the internet may not have responded. 
However, we were pleased to capture the views of 49 peo-
ple (32%) who indicated that they were unsure or unwill-
ing to participate in a CP genomics study. Furthermore, 
some degree of nonresponse bias may have been intro-
duced to the findings as the survey questions were not 
compulsory.
These results have limited generalizability as our popu-
lation was predominantly well-educated, female, parents 
from Australia. However, considering that individuals 
with CP and their families have previously not had an op-
portunity to give their opinions and attitudes regarding 
genetic research; this study offers an informative first step 
to understanding the perspective of a unique population.
Conclusions
In conclusion, our study identified several demo-
graphic and independent factors associated with a will-
ingness to participate. The majority of our respondents 
were supportive of international data and biospecimen 
sharing; however, there are diverse information require-
ments from the cohort. Thus, it is crucial that we now 
continue to work with these groups to better understand 
what information is important and how we can best con-
vey this, in order for families to not only make informed 
choices but to further promote trust between the partici-
pant and the researcher. The success of genomics research 
in CP is contingent upon broad, diverse, and culturally 
appropriate recruitment to ensure adequately powered 
sample sizes and equitable benefit. Engagement of fami-
lies and people with CP in genomics research practice and 
policy will maximize participant uptake and participa-
tion, which will in turn facilitate faster breakthroughs for 
people with CP.
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